A plain language summary of the ARAMIS study, that looked looked at the role of darolutamide in the treatment of patients with nonmetastatic, castration-resistant prostate cancer, has recently been published in Future Oncology. This Animated Video provides an overview of the plain language summary.
Read the full article ‘Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial’ here.